Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly EBITDA Margin came in at 29.02% in Q1 2026, up 2319.0% YoY from 1.2% in Q1 2025, and down 414.79% on a QoQ basis from 9.22% in Q4 2025.
Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of EBITDA Margin data on file, last reported at 29.02% in Q1 2026.
- Quarterly EBITDA Margin rose 2319.0% year-over-year to 29.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.41% (up 16450.0% YoY) and the FY2025 annual result came in at 675.53%, down 53665.0% from the prior year.
- EBITDA Margin retreated to 29.02% in Q1 2026, from 9.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 62.33% in Q3 2025 to a low of 336.53% in Q1 2024.
- A 5-year average of 171.83% and a median of 209.13% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin sank 34914 bps — and 2025, when it surged 28432 bps.
- Tracing TVTX's EBITDA Margin over 5 years: stood at 295.52% in 2022, then climbed by 29 bps to 209.13% in 2023, then jumped by 61 bps to 81.21% in 2024, then surged by 111 bps to 9.22% in 2025, then plunged by 415 bps to 29.02% in 2026.
- The last three EBITDA Margin figures came in at 29.02% (Q1 2026), 9.22% (Q4 2025), and 62.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 2.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.33% |
| Mar 31, 2026 | -29.02% |
| Dec 31, 2025 | 9.22% |
| Sep 30, 2025 | 62.33% |
| Jun 30, 2025 | -11.05% |
| Mar 31, 2025 | -52.21% |
| Dec 31, 2024 | -81.21% |
| Sep 30, 2024 | -89.27% |
| Jun 30, 2024 | -125.11% |
| Mar 31, 2024 | -336.53% |
| Dec 31, 2023 | -209.13% |
| Sep 30, 2023 | -249.59% |
| Jun 30, 2023 | -322.87% |
| Mar 31, 2023 | -315.23% |
| Dec 31, 2022 | -295.52% |
| Sep 30, 2022 | -294.23% |
| Jun 30, 2022 | -274.24% |
| Mar 31, 2022 | -307.45% |
| Dec 31, 2021 | 53.62% |
| Sep 30, 2021 | -46.49% |